Baidu, Intermune: Analysts' New Ratings

Editor's Note: Green and red arrows refer to intraday stock price movement.

NEW YORK ( TheStreet) -- CHANGE IN RATINGS

Baidu ( BIDU) rated new Buy at Jefferies. $200 price target. Company is a market leader with limited competition.

Comerica ( CMA) rated new Market Perform at Morgan Keegan. $38 price target. Visibility remains low for potential loan growth.

Fastenal ( FAST) upgraded at UBS from Neutral to Buy. $72 price target. Estimates also boosted, as sales growth can drive margin expansion.

Henry Schein ( HSIC) upgraded at Goldman to Buy, Goldman Sachs said. $80 price target. Industry should benefit from improving macro trends.

Intermune ( ITMN) upgraded to Outperform at Wells Fargo. Expecting a more robust Esbriet launch.

Perrigo ( PRGO) upgraded at from Sell to Neutral, Goldman Sachs said. $80 price target. Company can move past the FDA issue and should continue to realize synergies from recent deals.

Riverbed Technology ( RVBD) upgraded at ThinkEquity from Hold to Buy. $48 price target. Guidance confirms recent checks that show demand can recover.

Riverbed Technology ( RVBD) upgraded at Oppenheimer from Perform to Outperform, Oppenheimer said. $40 price target. Company pre-announced to the upside, easing some demand concerns.

Sirona Dental ( SIRO) rated new Buy at Goldman. Company was also addded to the Conviction Buy list. Company is leverage to increased spending on high-tech equipment. $61 price target.

Sunoco ( SUN) downgraded at Benchmark from Hold to Sell, Benchmark Company said. $34 price target. Company is facing an unfavorable settlement for coke pricing.

Dentsply ( XRAY) rated new Neutral at Goldman Sachs. $39 price target. Stock is already pricing in improving industry growth.

End of report.

This article was written by a staff member of TheStreet.

More from Stocks

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says

Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says

Video: Here Is Why Carvana Isn't Worried About Amazon

Video: Here Is Why Carvana Isn't Worried About Amazon

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat